{"id":"preservative-free-latanoprost","safety":{"commonSideEffects":[{"rate":"25–50","effect":"Conjunctival hyperemia"},{"rate":"10–20","effect":"Iris pigmentation increase"},{"rate":"10–15","effect":"Eyelash growth (hypertrichosis)"},{"rate":"5–15","effect":"Eye irritation or discomfort"},{"rate":"5–10","effect":"Periocular skin pigmentation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Latanoprost mimics the action of prostaglandin F2α by activating FP receptors on the ciliary muscle bundle and trabecular meshwork. This increases unconventional (uveoscleral) drainage of aqueous humor from the anterior chamber, reducing intraocular pressure. The preservative-free formulation eliminates potential irritation from benzalkonium chloride or other preservatives, improving tolerability in sensitive eyes.","oneSentence":"Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:39.400Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT06249152","phase":"PHASE2","title":"Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients","status":"COMPLETED","sponsor":"Qlaris Bio, Inc.","startDate":"2024-04-21","conditions":"Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma","enrollment":36},{"nctId":"NCT04133311","phase":"PHASE3","title":"A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2019-04-10","conditions":"Open-Angle Glaucoma or Ocular Hypertension, Ocular Surface Disease","enrollment":386},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":28},{"nctId":"NCT04957329","phase":"PHASE4","title":"Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-09-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":28},{"nctId":"NCT05606796","phase":"PHASE4","title":"Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos.","status":"UNKNOWN","sponsor":"Uzoma Chinyei Joan","startDate":"2022-12","conditions":"Effect of Drug","enrollment":76},{"nctId":"NCT04828057","phase":"","title":"Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2021-09-01","conditions":"Ocular Surface Disease, Primary Open Angle Glaucoma","enrollment":50},{"nctId":"NCT05165290","phase":"PHASE3","title":"Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure","status":"UNKNOWN","sponsor":"TearClear Corp","startDate":"2021-11-29","conditions":"Elevated Intraocular Pressure","enrollment":300},{"nctId":"NCT02585375","phase":"PHASE4","title":"Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2015-09-17","conditions":"Glaucoma, Ocular Hypertension","enrollment":70},{"nctId":"NCT04896125","phase":"","title":"Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-10-02","conditions":"Glaucoma; Ocular Disorders (I.E. Caused by Ocular Disorders)","enrollment":300},{"nctId":"NCT04891588","phase":"NA","title":"Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD","status":"UNKNOWN","sponsor":"Klinički Bolnički Centar Zagreb","startDate":"2021-03-08","conditions":"Primary Open-angle Glaucoma, Ocular Hypertension","enrollment":50},{"nctId":"NCT04743622","phase":"PHASE4","title":"Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost","status":"COMPLETED","sponsor":"CHA University","startDate":"2019-04-30","conditions":"Glaucoma, Ocular Hypertension","enrollment":57},{"nctId":"NCT03612817","phase":"PHASE4","title":"Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2017-01","conditions":"Glaucoma, Open-Angle","enrollment":42},{"nctId":"NCT02802137","phase":"PHASE4","title":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2015-03","conditions":"Glaucoma, Ocular Surface Disease","enrollment":43},{"nctId":"NCT01975714","phase":"PHASE4","title":"Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study","status":"COMPLETED","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2013-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":67},{"nctId":"NCT01369771","phase":"PHASE4","title":"The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma","status":"COMPLETED","sponsor":"FinnMedi Oy","startDate":"2010-08","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":30},{"nctId":"NCT01510145","phase":"PHASE4","title":"Efficacy of Changing to TRAVATAN® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-02","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":191},{"nctId":"NCT01493427","phase":"PHASE4","title":"Efficacy of Changing to TRAVATAN® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":202},{"nctId":"NCT01087671","phase":"PHASE3","title":"Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2010-04","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":185},{"nctId":"NCT01162603","phase":"PHASE4","title":"Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2011-03","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":40},{"nctId":"NCT00596791","phase":"PHASE3","title":"Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2008-01","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Monoprost"],"phase":"marketed","status":"active","brandName":"Preservative-free latanoprost","genericName":"Preservative-free latanoprost","companyName":"Association for Innovation and Biomedical Research on Light and Image","companyId":"association-for-innovation-and-biomedical-research-on-light-and-image","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}